Astellas Pharma (ALPMY) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALPMY shares.
View ALPMY analyst ratings or view top-rated stocks.

Astellas Pharma's stock was trading at $15.16 at the beginning of the year. Since then, ALPMY shares have increased by 5.9% and is now trading at $16.06.
View the best growth stocks for 2023 here.

Astellas Pharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 37,400 shares, an increase of 77.3% from the April 30th total of 21,100 shares. Based on an average trading volume of 89,000 shares, the short-interest ratio is currently 0.4 days.
View Astellas Pharma's Short Interest.

Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its quarterly earnings data on Thursday, April, 27th. The company reported $0.15 EPS for the quarter. The business had revenue of $2.68 billion for the quarter. Astellas Pharma had a trailing twelve-month return on equity of 12.64% and a net margin of 6.27%.

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.15 per share and currently has a dividend yield of 1.98%. The dividend payout ratio is 39.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ALPMY will have a dividend payout ratio of 13.27% next year. This indicates that the company will be able to sustain or increase its dividend.

Shares of Astellas Pharma split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly issued shares were payable to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALPMY stock can currently be purchased for approximately $16.06.

Astellas Pharma (OTCMKTS:ALPMY) has a market capitalization of $29.06 billion and generates $11.24 billion in revenue each year. The company earns $730.68 million in net income (profit) each year or $0.38 on an earnings per share basis.

The company employs 14,522 workers across the globe.

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The official website for the company is www.astellas.com. The company can be reached via phone at (133) 244-3000.